Alumis ALMS
NASDAQ ALMS
$6.35 -0.20 (-3.05%)
As of: Nov 10, 2026 · 3:35 PM EST

Alumis (ALMS) EBITDA Margin (2025 - 2026)

Updated

Alumis (ALMS) posted EBITDA Margin of -4954.80% for Q4 2025, up 581.31 percentage points from the prior quarter.

Analysis

Alumis (ALMS) EBITDA Margin (2025 - 2026) Analysis & Trends

For FY2025, Alumis' EBITDA Margin came in at -1872.38%.

  • Quarterly EBITDA Margin has run from a low of -5536.11% in Q3 2025 to a high of -578.65% in Q1 2025 over five years.
  • According to Business Quant data, EBITDA Margin for the three prior quarters was -5536.11% (Q3 2025), -5238.90% (Q2 2025) and -578.65% (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 54.65%
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 32.68%
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 46.88%
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 40.75%
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 46.62%
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 50.63%
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 42.49%
10 Alumis 830.27 Mn -881.19 Mn - -8,903.79%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -8,903.79%
Mar 31, 2026 -5,602.41%
Dec 31, 2025 -4,954.80%
Sep 30, 2025 -5,536.11%
Jun 30, 2025 -5,238.90%
Mar 31, 2025 -578.65%
API Access

Alumis EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ALMS&period=max&api_key=YOUR_API_KEY